Giovanni Caforio to step down as Bristol Myers CEO, with Chris Boerner named successor
Giovanni Caforio will step down as Bristol Myers Squibb’s CEO on Nov. 1, the New York pharma giant said Wednesday, as part of a broader leadership shakeup.
Caforio, 58, has worked at Bristol Myers since 2000 and has served as CEO since May 2015, overseeing a period of growth that included the $74 billion acquisition of Celgene. When he steps down later this year, Caforio will serve as executive chairman, according to a news release, and Chris Boerner will take the reins as the next CEO of the $143 billion company. Boerner has been BMS’ chief commercialization officer, with the pharma naming him chief operating officer effective immediately.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.